


Claims

1. A compound of the formula,



wherein

R^1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;


R^2 is hydrogen or methyl;

R^3 is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1, wherein R^1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, or (L)-ornityl-(D)-ornitylamino.
3. The compound according to Claim 1, wherein R^2 and R^3 are hydrogen.
4. The compound according to Claim 1, wherein R^1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, and R^2 and R^3 are hydrogen.

5. The compound according to Claim 1, wherein R^1 is (L)-ornityl-(D)-ornitylamino, and R^2 and R^3 are hydrogen.
6. The compound according to Claim 1, wherein R^1 is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R^2 and R^3 are hydrogen.
7. The compound according to Claim 1, wherein R^1 is N-(3-aminopropyl)-N-[(2R)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R^2 and R^3 are hydrogen.
8. The compound according to Claim 1, wherein R^1 is N-(3-aminopropyl)-N-[(2S)-5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, and R^2 and R^3 are hydrogen.
9. The compound according to Claim 1, wherein R^1 is N-(2-aminoethyl)-N-[(2S)-5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, and R^2 and R^3 are hydrogen.
10. The compound according to Claim 1 wherein R^2 is methyl and R^3 is hydrogen.
11. The compound according to Claim 1 wherein R^2 is hydrogen and R^3 is hydroxyl.
12. A pharmaceutical composition comprising a mixture of a pharmaceutically acceptable carrier and an effective amount of a compound of the formula



wherein


R^1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;

R^2 is hydrogen or methyl;

R^3 is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.

13. A method for the prophylactic and/or therapeutic treatment of mycoses which comprises administering to a human being or an animal an effective amount of the compound of the formula



wherein

R^1 is N-(3-aminopropyl)-N-[(2S)-2,5-diaminovaleryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino, N-(3-aminopropyl)-N-[5-amino-2-[N-(3-aminopropyl)amino]valeryl]amino, N-(2-aminoethyl)-N-[5-amino-2-[N,N-bis(2-aminoethyl)amino]valeryl]amino or ornityl-ornitylamino;

R^2 is hydrogen or methyl;

R^3 is hydrogen or hydroxy;

or a pharmaceutically acceptable salt thereof.
